Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2018
November 17, 2018 at 03:41 am IST
Share
Nuo Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced total revenue was USD 260,280 compared to USD 162,196 a year ago. Operating loss was USD 411,794 compared to USD 1.375 million a year ago. Net loss was USD 649,878 compared to USD 1.376 million a year ago. Basic loss per share was USD 0.03 compared to USD 0.09 a year ago. For the nine months, total revenue was USD 558,532 compared to USD 523,539 a year ago. Operating loss was USD 1.662 million compared to USD 6.970 million a year ago. Net loss was USD 1.910 million compared to USD 6.981 million a year ago. Basic loss per share was USD 0.08 compared to USD 0.59 a year ago.
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.